Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93291Research ArticleKombinatsiya blokatora renin-angiotenzinovoy sistemy/digidropiridinovogo antagonista kal'tsiya i nefroprotektsiya u patsientov s sakharnym diabetomKobalavaZh. D-KotovskayaYu. V-151220101212444828122021Copyright © 2010, Consilium Medicum2010[Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр). Кардиоваск. тер. профил. 2008; 4 (Прил.).][Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.][K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5 Suppl. 1): S1–290.][Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58.][Функциональное состояние почек и прогнозирование сердечно - сосудистого риска. Рекомендации Всероссийского общества кардиологов и Научного общества нефрологов России. Кардиоваск. тер. и проф. 2008; 7 (6): Прил. 3 http://www.scardio.ru/downloads/c4m0i228][www.fda.gov][Boersma C, Atthobari J, Gansevoort R.T et al. Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making. Pharmacoeconomics 2006; 24 (6): 523–35.][Hollenberg N.K, Parving H-H, Viberti G et al. Albuminuria response to very high - dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921–6.][Viberti G. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure – Independent Effect. Wheeldon and for the Microalbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Circulation 2002; 106: 672–8.][The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of Microalbuminuria in Patients with Type 2 Diabetes. Diabetes Care; 2007; 30 (6): 1581–3.][Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999–1007.][Lambers Heerspink H.J, Ninomiya T, Perkovic V et al. for the ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J doi:10.1093/eurheartj/ehq139][Brenner B.M, Cooper M.E, de Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861–9.][Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.][Bakris G.L, Sarafi dis P.A, Weir M.R et al., for the ACCOMPLISH Trial investigators. Renal outcomes with diff erent fi xed - dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecifi ed secondary analysis of a randomized controlled trial. Lancet 2010.][Jamerson K, Weber M.A, Bakris G.L et al., for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high - risk patients. N Engl J Med 2008; 359: 2417–28.][Bakris G.L, Weir M.R. Angiotensin converting enzyme inhibitor - associated elevations in serum creatinine is this a cause for concern? Arch Intern Med 2000; 160: 685–93.][Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999–1007.][Delles C, Klingbeil A.U, Schneider M.P et al. Direct comparison of the eff ects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens 2003; 16: 1030–5.][Sarafidis P.A, Bakris G, Weber M et al. Changes in glomerular filtration rate with benazepril plus amlodipine or benazepril plus hydrochlorothiazide treatment in hypertensive patients at high risk; an analysis of the ACCOMPLISH trial. World Congress of Nephrology, Milan, Italy; May 23, 2009: Sa199 (abstr). http://www.abstracts2view.com/wcn/view.php?nu=WCN09L_455 (accessed Jan 7, 2010).][Bakris G.L, Toto R.D, Mc Cullough P.A et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73: 1303–9.][Herlitz H, Harris K, Risler T et al. The eff ects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16: 2158–65.][Kaneshiro Y, Ichihara A, Sakoda M et al. Add - on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. Kidney Blood Press Res 2009; 32 (1): 51–8.][Yilmaz M.I, Carrero J.J, Martin-Ventura J.L et al. Combined Therapy with Renin - Angiotensin System and Calcium Channel Blockers in Type 2 Diabetic Hypertensive Patients with Proteinuria: Effects on Soluble TWEAK, PTX3, and Flow-Mediated Dilation. Clin J Am Soc Nephrol 5: 1174–81.]